Lexeo Therapeutics (LXEO) Preferred Stock Liabilities (2022 - 2023)
Lexeo Therapeutics (LXEO) reported Preferred Stock Liabilities of $85.3 million for Q3 2023, down 53.92% on a YoY basis from $185.0 million in Q3 2022, and down 53.92% sequentially from $185.0 million in Q2 2023.
Lexeo Therapeutics (LXEO) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends
Lexeo Therapeutics (LXEO) has 2 years of Preferred Stock Liabilities data on file, last reported at $85.3 million in Q3 2023.
- For the quarter ending Q3 2023, Preferred Stock Liabilities fell 53.92% year-over-year to $85.3 million; the trailing twelve-month figure through Sep 2023 stood at $85.3 million (down 53.92% YoY), and the FY2022 full-year result was $185.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities fell to $85.3 million in Q3 2023, from $185.0 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $185.0 million in Q3 2022 to a low of $85.3 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lexeo Therapeutics | 382.38 Mn | 382.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 85.27 Mn |
| Jun 30, 2023 | 185.03 Mn |
| Mar 31, 2023 | 185.03 Mn |
| Dec 31, 2022 | 185.03 Mn |
| Sep 30, 2022 | 185.03 Mn |